In addition, experimental models demonstrated that either high dose injection of IL-2 alone, adoptive transfer of ex vivo cultured lymphocytes, or concurrent IL-2 and lymphocyte administration could deliver potent anti-tumor activity (30–32, 41–45). Here, IL2 is linked to neoplasm.